Source trace. Via News points to the documents behind its reporting and shows what we drew from each — so you can check any claim. How we source

Source document· May 28, 2026

Pfizer and Innovent Biologics Enter Global Strategic Collaboration to Accelerate Development of Innovative Oncology Medicines

View original at finance.yahoo.com

Pfizer and Innovent Biologics Enter Global Strategic Collaboration to Accelerate Development of Innovative Oncology Medicines NEW YORK & SAN FRANCISCO & SUZHOU, China, May 28, 2026--(BUSINESS WIRE)--Pfizer Inc…

Opening lines of the source · short snapshot — read the full document at the original

What we drew from this source

The claims Via News extracted from this document. We point to the source; we don't replace it.

The agreement leverages complementary resources to develop Innovent's early-stage oncology pipeline with greater speed and global impact, expanding Innovent's reach via co-commercialization in the U.S. and Europe and laying the foundation for a global oncology platform.
60% confidence
The collaboration combines Innovent's discovery and early clinical development with Pfizer's global R&D and commercialization capabilities to accelerate breakthroughs that can redefine standards of care for cancer patients.
60% confidence

Data points we hold from this source

Pfizer Inc. · collaboration program count	12 programs
Pfizer Inc. · discovery programs contributed to collaboration	4 programs